



OPEN ACCESS

Original research

# Misdiagnosis of prolonged psychogenic non-epileptic seizures as status epilepticus: epidemiology and associated risks

Johannes Jungilligens <sup>1</sup>, Rosa Michaelis <sup>1,2</sup>, Stoyan Popkirov <sup>1</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2021-326443>).

<sup>1</sup>Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany

<sup>2</sup>Department of Neurology, Gemeinschaftskrankenhaus Herdecke, University of Witten/Herdecke, Witten, Germany

## Correspondence to

Dr Johannes Jungilligens, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, 44892 Bochum, Germany; [johannes.jungilligens@rub.de](mailto:johannes.jungilligens@rub.de)

Received 19 February 2021

Accepted 21 July 2021

Published Online First 6 August 2021

## ABSTRACT

**Objective** To determine the epidemiology of prolonged psychogenic non-epileptic seizures (pPNES) misdiagnosed as status epilepticus, as well as the risks associated with non-indicated treatment.

**Methods** We performed an individual patient data analysis from the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) and the Established Status Epilepticus Treatment Trial (ESETT) to assess incidence, patient characteristics and clinical course of misdiagnosed pPNES.

**Results** Among 980 patients aged 8 years or older diagnosed and treated for status epilepticus in RAMPART and ESETT, 79 (8.1%) were discharged with a final diagnosis of pPNES. The relative incidence was highest in adolescents and young adults (20.1%). The typical female preponderance seen in that age bracket was not evident in children and older adults. Adverse effects, including respiratory depression and intubation, were documented in 26% of patients with pPNES receiving benzodiazepines in RAMPART and 33% of patients receiving additional second-line medication in ESETT. In ESETT, patients who were treated with benzodiazepines before hospital admission had higher rates of unresponsiveness and severe adverse effects than those treated after admission, suggesting cumulative effects of accelerated treatment momentum. Across trials, one in five patients with pPNES were admitted to an intensive care unit.

**Conclusions** Misdiagnosis and treatment of pPNES as status epilepticus are a common and widespread problem with deleterious consequences. Mitigating it will require training of emergency staff in semiological diagnosis. Status epilepticus response protocols should incorporate appropriate diagnostic re-evaluations at each step of treatment escalation, especially in clinical trials.

## INTRODUCTION

Status epilepticus is thought to cause irreversible harm after more than 30 min of ongoing convulsions, so early aggressive treatment is recommended by most guidelines.<sup>1</sup> Within minutes, benzodiazepines should be administered as first-line medication, with high-dose antiepileptic drugs and intubation as second-line and third-line treatment in cases of refractory seizure activity. This compression of treatment timeframes has proven beneficial for the majority of patients with status epilepticus.<sup>2</sup> However, this treatment imperative can come at the cost of diagnostic accuracy in emergencies.

The main differential to consider when assessing patients with suspected (convulsive) status epilepticus are dissociative seizures, also known as functional or psychogenic non-epileptic seizures (PNES). Prolonged PNES (pPNES) are reported by 78% of patients with PNES and lead to emergency admissions to the intensive care unit (ICU) in 18%–27% of patients.<sup>3,4</sup> Acute pharmacological treatment is not indicated as pPNES are usually self-limited and do not respond to medication (beyond the occasional placebo response or deep sedation). pPNES generate no direct secondary physical harm to patients and should be treated with verbal and behavioural interventions only.

As clinical differentiation between epileptic seizures and PNES requires specific semiological expertise, and the treatment imperative for presumed status epilepticus demands almost immediate decision-making, misdiagnosis is common in emergency settings and pPNES are often treated mistakenly with non-indicated medication. Retrospective reviews suggest that patients with misdiagnosed pPNES often receive benzodiazepines (at even higher doses than patients with status epilepticus)<sup>5</sup> and frequently require endotracheal intubation as a consequence.<sup>6</sup> Of note, pPNES are the foremost determinant of healthcare utilisation costs in patients with PNES.<sup>4,7</sup>

A systematic look at treatment trials for status epilepticus presenting to emergency services (table 1, online supplemental figure 1) reveals that misdiagnosis of pPNES as status epilepticus occurs in various settings and at all levels of treatment: prehospital and in the emergency department; and first-line and second-line therapy. Misdiagnosis is common in both adult and paediatric populations and in both paramedic-led and physician-led emergency services.<sup>8–17</sup> Remarkably, none of the listed trials had specific procedures in place to recognise and exclude pPNES from study enrolment, nor did they specify protocols for treatment reallocation in cases of misdiagnosis.

To better understand the epidemiology of pPNES misdiagnosed as status epilepticus as well as the risks of harm from non-indicated treatment, we performed an individual patient data analysis from the two largest status epilepticus treatment trials to date: the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART)<sup>10</sup> and the Established Status Epilepticus Treatment Trial (ESETT).<sup>16,17</sup> We then discuss strategies that may improve recognition of pPNES within emergency medical services



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Jungilligens J, Michaelis R, Popkirov S. *J Neurol Neurosurg Psychiatry* 2021;**92**:1341–1345.

**Table 1** Status epilepticus trials for emergency presentations reporting rate of misdiagnosis

Study	Centres (n), country	Age group	Initial diagnosis made by	Sample size	Rate of misdiagnosis (%)	Proportion of misdiagnoses specified as pPNES
Leppik <i>et al</i> <sup>8</sup>	3, USA	Adults	Physicians, hospital-based	78	13.5	1/11
Allredge <i>et al</i> <sup>9</sup>	10, USA	Adults	Paramedics	205	5	10/10
Silbergleit <i>et al</i> <sup>10*</sup>	79, USA	Both (children ≥40 kg)	Paramedics	893	7.1	63/63
Chamberlain <i>et al</i> <sup>11</sup>	11, USA	Paediatric (3 months–18 years)	Physicians, hospital-based	310	10	ns
Mundlamuri <i>et al</i> <sup>12</sup>	1, India	Both (15–65 years)	Physicians, hospital-based	150	0.05	1/1
Sánchez Fernández <i>et al</i> <sup>13</sup>	9, USA	Paediatric (1 month–21 years)	Paramedics	81	0	–
Welch <i>et al</i> <sup>14*</sup>	79, USA	Paediatric (weight ≥13 kg)	Paramedics	120	8.3	8/10
Navarro <i>et al</i> <sup>15</sup>	39, France	Adults	Physicians, prehospital	136	4.4	6/6
Kapur <i>et al</i> <sup>16†</sup>	57, USA	Both (≥2 years)	Physicians, hospital-based	384	9.6	37/37
Chamberlain <i>et al</i> <sup>17†</sup>	58, USA	Both (≥2 years)	Physicians, hospital-based	462	ns‡	ns‡

See online supplemental material for search strategy and flow diagram of literature review.

\*Publication part of RAMPART.

†Publication part of ESETT.

‡See the Results section for the results of individual patient data analysis.

ESETT, Established Status Epilepticus Treatment Trial; ns, not specified; pPNES, prolonged psychogenic non-epileptic seizures; RAMPART, Rapid Anticonvulsant Medication Prior to Arrival Trial.

and offer recommendations to improve future status epilepticus response protocols in clinical practice and treatment trials.

## METHODS

We analysed available primary data from the two largest status epilepticus treatment trials to date. RAMPART (ClinicalTrials.gov identifier: NCT00809146) is a randomised, double-blind trial comparing intramuscular versus intravenous benzodiazepine as first-line therapy for status epilepticus, which comprised 1023 cases from 893 patients enrolled between June 2009 and January 2011. After excluding cases with eligibility violations, incorrect study medication/dose assignment, repeated enrolment, etc (see original publication for details), 732 patients were included in the final per-protocol analysis. In addition, we analysed data of ESETT (ClinicalTrials.gov identifier: NCT01960075), which comprises 478 cases from 462 patients enrolled between November 2015 and December 2018 at 58 hospital emergency departments across the USA.<sup>16 17</sup> ESETT is a randomised, double-blind study to compare the effectiveness of levetiracetam, fosphenytoin and valproate in patients with established status epilepticus unresponsive to treatment with benzodiazepines. Thus, we base our analysis on data from combined 1210 individual patients. We focus on patients who were discharged with a final diagnosis of non-epileptic seizures. The study protocols of RAMPART and ESETT provided no formal definition or diagnostic criteria (including Electroencephalogram [EEG] requirements) regarding this final diagnosis. We limited our analysis to trial participants aged eight years or older, as PNES can rarely be diagnosed in children younger than this.<sup>18–20</sup> To assess the relative rate of misdiagnosis, patients' age was stratified into six age brackets: children (8–14 years), adolescents and young adults (15–29 years), younger middle-aged adults (30–44 years), older middle-aged adults (45–59 years), old adults (60–74 years) and very old adults (≥75 years).

Within these trials, adverse events were graded according to the National Institute of Health's (NIH) Common Terminology Criteria for Adverse Events and categorised according to the Medical Dictionary for Regulatory Activities classification.  $\chi^2$  test and Fisher's exact test were used for between-group analyses. The level of significance was  $p < 0.05$ .

## RESULTS

Among 1210 patients diagnosed and treated as status epilepticus, 980 were aged eight years or older. Of these patients, 79 (8.1%) were discharged with a final diagnosis of pPNES. Of these, 55 (70%) were female and the mean age was 32.6 years (SD: 15.9 years), ranging from eight to 84 years.


Compared with patients with status epilepticus, the relative prevalence of pPNES across age groups was significantly different ( $\chi^2(10) = 66.838$ ,  $p < 0.001$ ), indicating a significant association between age and diagnosis (figure 1). The relative prevalence of pPNES was highest among adolescents and younger adults aged 15–29 years, with 20.1% of these patients (38 of 189) eventually recognised as having had pPNES.

Patients with pPNES were misdiagnosed and mistakenly treated for status epilepticus at 39 different study centres, confirming that this is a widespread phenomenon.

### First-line treatment

Regarding the effects of first-line treatment with benzodiazepines, the 46 patients with pPNES from the RAMPART data were analysed. In 14 (30%) patients, prehospital study medication (10 mg intramuscular midazolam plus intravenous placebo, or 4 mg intravenous lorazepam plus intramuscular placebo) was not followed by seizure termination within 10 min or before arrival at the hospital (primary endpoint). On hospital arrival, seven (15%) patients were directly admitted to the ICU, while twelve (26%) patients were admitted to a non-ICU unit and 27 (59%) patients were discharged directly from the emergency department. Those admitted to the ICU remained there for a median of one day (range 1–7 days). Overall, the hospital stay of admitted patients had a median duration of three days (range 1–7 days).

In twelve (26%) patients, a total of 17 adverse events were recorded (online supplemental table S1 presents an overview of all adverse events and their grading across RAMPART and ESETT patients). One of these events—a case of respiratory depression—was reported as being possibly related to the study intervention and led to intubation.



**Figure 1** Relative prevalence of prolonged psychogenic non-epileptic seizures in patients overall, by age group and gender.

### Second-line treatment

Cumulative effects of first-line and second-line treatment (levetiracetam, fosphenytoin and valproate) were assessed using data from 33 patients with pPNES unresponsive to antecedent first-line benzodiazepine treatment within ESETT.

Of the 28 patients for whom information on timing of first-line medication was available, 18 (55%) received benzodiazepines before arriving at the emergency department and the rest were medicated in-hospital. Ten patients (31%) were admitted to the ICU and remained there for up to twelve days (median: one day). Twelve patients (36%) were admitted to a non-ICU unit, and eleven (33%) were discharged directly from the emergency department. Overall, the hospital stay of admitted patients had a median duration of one day (range 1–12 days).

All patients were assessed for seizure manifestations and responsiveness at 20 and at 60 min after the start of the study drug administration. At 20 min assessment, clinically apparent seizures were observed in nine (27%) patients; at that time, responsiveness to verbal or noxious stimuli was not improved in eleven (33%) patients. At the 60 min assessment, three patients still had clinically apparent seizures (9%), while responsiveness was still not improved in nine patients (27%). The Richmond Agitation Sedation Scale was administered at the 60 min assessment (table 2). Nine patients (27%) were deeply sedated or unarousable at this point.

In eleven (33%) patients, a total of 13 adverse events were recorded (online supplemental table S1), four of which were rated as 'serious'. Four events were reported as being likely

**Table 2** Richmond Agitation Sedation Scale (RASS) score of patients with pPNES from ESETT at 60 min assessment

RASS score	Cases	%
+1 restless	3	9.1
0 alert	4	12.1
-1 drowsy	7	21.2
-2 light sedation	7	21.2
-3 moderate sedation	3	9.1
-4 deep sedation	6	18.2
-5 unarousable	3	9.1

ESETT, Established Status Epilepticus Treatment Trial; pPNES, prolonged psychogenic non-epileptic seizures.

related to the study intervention: abdominal pain, hypersensitivity, hypotension and pruritus. The adverse events were graded as more severe in patients who received benzodiazepines before emergency department arrival than those who did not (Fisher's exact test=10.455,  $p=0.033$ ). In two patients (6%), endotracheal intubation was performed. The adverse events leading to intubation were documented as 'depressed level of consciousness' in one case and 'cerebrovascular accident' in the other case.

### DISCUSSION

In this individual patient data analysis from the two largest status epilepticus trials to date, we found that among patients aged 8 or older the overall rate of misdiagnosed pPNES was 8.1% and up to 20.1% in adolescents and young adults. This age group also showed the typical female preponderance for PNES, while gender distribution tended to equalise in children and older adults, in line with previous observations.<sup>21 22</sup> The annual incidence of confirmed status epilepticus presenting to the emergency department is reported as 16 per 100 000.<sup>23</sup> Based on our analysis, the extrapolated incidence of misdiagnosed pPNES receiving non-indicated medication can be conservatively estimated at around 1.3 per 100 000 inhabitants per year, which is equal to that of cerebral venous and sinus thrombosis in the general population.<sup>24</sup>

As treatment is required to commence as soon as 5 min after seizure onset, a certain degree of aetiology-agnostic emergency decision-making can be encountered in response algorithms for ongoing seizures (i.e., 'shoot first, ask questions later').<sup>25</sup> Two common misconceptions might contribute to this approach: (1) benzodiazepines will also be helpful for PNES, and (2) potential adverse effects of benzodiazepines and further escalation of treatment are negligible. Our analysis clearly disproves both of these assumptions. Benzodiazepine treatment does not reliably terminate seizure activity, as 30% of RAMPART patients with pPNES had ongoing seizures after receiving the study medication. Adverse effects in RAMPART were reported in 26% of patients with pPNES, including respiratory depression requiring intubation. By design, all participants in ESETT had ongoing seizures despite substantial doses of benzodiazepines at the time of study enrolment, further demonstrating that benzodiazepines should not be expected to effectively halt PNES. Moreover, 27% of patients with pPNES in ESETT remained deeply sedated at 1 hour after second-line treatment. Although benzodiazepines are not known to cause central apnoea, they depress genioglossus activity and can lead to obstructive apnoea requiring intubation.<sup>26</sup> Obesity-related obstructive breathing disorders are common in patients with PNES,<sup>27</sup> so this poses a particular danger in this patient group.



Admission to the ICU was necessary in 15% of patients with pPNES in RAMPART and twice that rate in ESETT (31%). The experience of being treated in an ICU can be highly distressing in itself and can lead to ICU-related post-traumatic stress disorder at a significant rate. Known risk factors for this are premorbid depression, negative emotionality, treatment-seeking behaviours and benzodiazepine sedation,<sup>28</sup> revealing a particularly dangerous constellation for patients with pPNES.<sup>29</sup> Lastly, some patients with pPNES were eventually intubated in both trials, an ultimate treatment escalation which has been reported at high rates previously<sup>6</sup> and harbours well-known risks of its own.<sup>30</sup>

An interesting observation regarding the momentum of the status epilepticus treatment imperative could be made from the ESETT data: patients who were treated with benzodiazepines before arrival at the emergency department had higher rates of unresponsiveness and severe adverse effects in the course of treatment and were more likely to be intubated than those treated in-hospital only. This could be explained by more severe seizure manifestations at onset, but alternatively prehospital interventions might accelerate the momentum of treatment, leading to higher medication doses overall and lowering the threshold for treatment escalation. It is worth noting that invasive overtreatment of pPNES can be potentially lethal.<sup>31</sup> In a recent cohort study, patients with video EEG-confirmed PNES (and no sign of comorbid epilepsy) had a more than doubled standardised mortality ratio, and the cause of death was documented as 'epilepsy' in 13 of 55 cases (24%), suggesting the possibility of misdiagnosis and associated iatrogenic harm.<sup>32</sup> Therefore, the trade-off between early and aggressive treatment to terminate persistent epileptic seizure activity and investing time to rule out or confirm the possibility of pPNES to avoid iatrogenic harm must be weighed carefully.

Another factor underlying the 'shoot first' mentality of convulsive status treatment is the purported lack of reliability of semiological seizure diagnosis. Indeed, semiology alone can be insufficient for a firm diagnosis for many types of seizures and seizure-like events. However, suspected convulsive status epilepticus has pronounced motor symptoms, allowing for a confident diagnosis on clinical grounds in most cases. A recent study on smartphone video recordings of seizures found that convulsive PNES can be identified with 96% accuracy on video.<sup>33</sup> Moreover, examination of ongoing seizures allows for quick assessment of interactive responsivity (e.g., resistance to eye-opening, preservation of pupillary and eyelash reflexes, change in seizure intensity in response to others), which can offer near-absolute specificity for PNES.<sup>34,35</sup> Filming an ongoing seizure for later specialist evaluation should be encouraged as a critical diagnostic intervention and can be justified as such even without prior consent.<sup>2</sup> Paramedics, emergency department staff, neurologists, and intensivists should be sensitised regarding the relative incidence of PNES and trained in semiological recognition of seizure types to reduce the rate of misdiagnosis and the risk of harm from overtreatment. The importance of obtaining ictal video, early EEG and postictal laboratory markers such as prolactin and creatine kinase should inform emergency work-up algorithms to reduce misdiagnosis.

The observed rates of pPNES misdiagnosis and risks of harm from non-indicated treatment should give cause to reconsider status epilepticus response protocols, especially in clinical trials. Highly specific semiological indicators of pPNES should be considered at enrolment and pPNES should be explicitly listed as exclusion criteria. Clinical reassessment, possibly operationalised through semiological checklists, should further be required at every step of treatment escalation. As misdiagnosed

pPNES can be expected at a rate of 5%–10%, specific protocols for de-escalation and reallocation of treatment should ideally be provided to trialists. Lastly, study analysis plans should include separate epidemiological and safety subanalyses for patients later diagnosed with pPNES.

**Contributors** JJ and SP formulated the initial study idea. RM contributed to refinement of the structure. RM managed the systematic literature review. JJ performed the data preparation and data analysis. SP and RM advised on evaluation. SP formulated the discussion. All authors contributed to the discussion, writing the manuscript and reviewed the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** SP receives royalties from Springer for a book on functional neurological disorders. The other authors declare no conflicts of interest.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. This research is based on the National Institute of Neurological Disease and Stroke's Archived Clinical Research data of RAMPART ('Rapid Anticonvulsant Medication Prior to Arrival Trial', PIs: Silbergleit, R, Lowenstein, DH and Durkalski, VL) and ESETT ('A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus', PIs: Silbergleit R, Chamberlain J and Elm J) received from the Archived Clinical Research Dataset website (<https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research/Archived-Clinical-Research-Datasets>).

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Johannes Junglillgens <http://orcid.org/0000-0002-4846-8337>

Rosa Michaelis <http://orcid.org/0000-0002-2577-0824>

Stoyan Popkirov <http://orcid.org/0000-0001-6168-0036>

#### REFERENCES

- 1 Trinkka E, Cock H, Hesdorffer D, *et al*. A definition and classification of status epilepticus—Report of the ILAE Task Force on Classification of Status Epilepticus. *Epilepsia* 2015;56:1515–23.
- 2 Crawshaw AA, Cock HR. Medical management of status epilepticus: emergency room to intensive care unit. *Seizure* 2020;75:145–52.
- 3 Reuber M, Pukrop R, Mitchell AJ, *et al*. Clinical significance of recurrent psychogenic nonepileptic seizure status. *J Neurol* 2003;250:1355–62.
- 4 Seneviratne U, Low ZM, Low ZX, *et al*. Medical health care utilization cost of patients presenting with psychogenic nonepileptic seizures. *Epilepsia* 2019;60:349–57.
- 5 Holtkamp M, Othman J, Buchheim K, *et al*. Diagnosis of psychogenic nonepileptic status epilepticus in the emergency setting. *Neurology* 2006;66:1727–9.
- 6 Viarasilpa T, Panyavachiraporn N, Osman G, *et al*. Intubation for psychogenic non-epileptic attacks: frequency, risk factors, and impact on outcome. *Seizure* 2020;76:17–21.
- 7 Seneviratne U, Minato E, Paul E. How reliable is ictal duration to differentiate psychogenic nonepileptic seizures from epileptic seizures? *Epilepsy Behav* 2017;66:127–31.
- 8 Leppik IE, Derivan AT, Homan RW, Leppik Ilo E, *et al*. Double-Blind study of lorazepam and diazepam in status epilepticus. *JAMA* 1983;249:1452.
- 9 Alldredge BK, Gelb AM, Isaacs SM, *et al*. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. *N Engl J Med* 2001;345:631–7.
- 10 Silbergleit R, Durkalski V, Lowenstein D, *et al*. Intramuscular versus intravenous therapy for prehospital status epilepticus. *N Engl J Med* 2012;366:591–600.

- 11 Chamberlain JM, Okada P, Holsti M, *et al.* Lorazepam vs diazepam for pediatric status epilepticus. *JAMA* 2014;311:1652.
- 12 Mundlamuri RC, Sinha S, Subbakrishna DK, *et al.* Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam—Pilot study. *Epilepsy Res* 2015;114:52–8.
- 13 Sánchez Fernández I, Abend NS, Agadi S, *et al.* Time from convulsive status epilepticus onset to anticonvulsant administration in children. *Neurology* 2015;84:2304–11.
- 14 Welch RD, Nicholas K, Durkalski-Mauldin VL, *et al.* Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. *Epilepsia* 2015;56:254–62.
- 15 Navarro V, Dagron C, Elie C, *et al.* Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. *Lancet Neurol* 2016;15:47–55.
- 16 Kapur J, Elm J, Chamberlain JM, *et al.* Randomized trial of three anticonvulsant medications for status epilepticus. *N Engl J Med* 2019;381:2103–13.
- 17 Chamberlain JM, Kapur J, Shinnar S, *et al.* Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. *Lancet* 2020;395:1217–24.
- 18 Plioplys S, Doss J, Siddarth P, *et al.* A multisite controlled study of risk factors in pediatric psychogenic nonepileptic seizures. *Epilepsia* 2014;55:1739–47.
- 19 Doss J, Caplan R, Siddarth P, *et al.* Risk factors for learning problems in youth with psychogenic non-epileptic seizures. *Epilepsy Behav* 2017;70:135–9.
- 20 Kozłowska K, Chudleigh C, Cruz C, *et al.* Psychogenic non-epileptic seizures in children and adolescents: Part I - Diagnostic formulations. *Clin Child Psychol Psychiatry* 2018;23:140–59.
- 21 Duncan R, Oto M, Martin E, *et al.* Late onset psychogenic nonepileptic attacks. *Neurology* 2006;66:1644–7.
- 22 Operto FF, Coppola G, Mazza R, *et al.* Psychogenic nonepileptic seizures in pediatric population: a review. *Brain Behav* 2019;9:e01406.
- 23 Nazerian P, Lazzeretti D, Vanni S, *et al.* Incidence, management and short-term prognosis of status epilepticus in the emergency department: a population survey. *Eur J Emerg Med* 2019;26:228–30.
- 24 Weimar C. Diagnosis and treatment of cerebral venous and sinus thrombosis. *Curr Neurol Neurosci Rep* 2014;14:417.
- 25 Gloss D, Weisberg L. *Neurology for the specialty boards*. Lippincott Williams & Wilkin, 2006.
- 26 Gueye PN, Lofaso F, Borron SW, *et al.* Mechanism of respiratory insufficiency in pure or mixed drug-induced coma involving benzodiazepines. *J Toxicol Clin Toxicol* 2002;40:35–47.
- 27 Popkirov S, Stone J, Derry CP. Abnormal sleep in patients with epileptic or dissociative (non-epileptic) seizures: a polysomnography study. *Eur J Neurol* 2019;26:255–60.
- 28 Marra A, Pandharipande PP, Patel MB. Intensive care unit delirium and intensive care Unit-Related posttraumatic stress disorder. *Surg Clin North Am* 2017;97:1215–35.
- 29 Popkirov S, Asadi-Pooya AA, Duncan R, *et al.* The aetiology of psychogenic non-epileptic seizures: risk factors and comorbidities. *Epileptic Disord* 2019;21:529–47.
- 30 Cook T, Behringer EC, Bengner J. Airway management outside the operating room. *Curr Opin Anaesthesiol* 2012;25:461–9.
- 31 Reuber M, Baker GA, Gill R, *et al.* Failure to recognize psychogenic nonepileptic seizures may cause death. *Neurology* 2004;62:834–5.
- 32 Nightscales R, McCartney L, Auvrez C, *et al.* Mortality in patients with psychogenic nonepileptic seizures. *Neurology* 2020;95:e643–52.
- 33 Tatum WO, Hirsch LJ, Gelfand MA, *et al.* Assessment of the predictive value of outpatient smartphone Videos for diagnosis of epileptic seizures. *JAMA Neurol* 2020;77:593.
- 34 Syed TU, LaFrance WC, Kahrman ES, *et al.* Can semiology predict psychogenic nonepileptic seizures? A prospective study. *Ann Neurol* 2011;69:997–1004.
- 35 Wardrope A, Wong S, McLaughlan J, *et al.* Peri-ictal responsiveness to the social environment is greater in psychogenic nonepileptic than epileptic seizures. *Epilepsia* 2020;61:758–65.

## SUPPLEMENTARY MATERIAL

### **Misdiagnosis of prolonged psychogenic nonepileptic seizures as status epilepticus: incidence and associated risks**

#### Authors:

Johannes Jungilligens \*<sup>a</sup>

Rosa Michaelis<sup>a, b</sup>

Stoyan Popkirov<sup>a</sup>

#### Affiliations:

<sup>a</sup> Department of Neurology, University Hospital Knappschafts Krankenhaus Bochum, Ruhr University Bochum, Bochum, Germany

<sup>b</sup> Department of Neurology, Gemeinschafts Krankenhaus Herdecke, University of Witten/Herdecke, Herdecke, Germany


#### \* Corresponding author:

Johannes Jungilligens, Dr. rer. nat.

Postal address: Klinik für Neurologie, Universitätsklinikum Knappschafts Krankenhaus Bochum, In der Schornau 23-25, 44892 Bochum, Germany.

E-Mail: johannes.jungilligens@rub.de

Phone: +49-234-299-0

**Figure S1: Flow diagram of literature review**

*Supplementary figure 1: An electronic search was performed using the MEDLINE database. The search was restricted to articles published up to January 2021. There were no language restrictions. We searched for clinical studies and clinical trials by using the Medical Subject Heading (Mesh) "Status Epilepticus/therapy". Clinical trials that recruited prehospital patients with status epilepticus and reported rates of misdiagnosis were eligible. Abstracts of the citations identified by the search were reviewed to determine eligibility for inclusion. We obtained full-text copies of all publications that might conceivably contain relevant data. The reference lists of all relevant publications were also examined for additional relevant studies*

**Table S1: Grading and MedDRA categorisation of adverse events in pPNES patients across RAMPART and ESETT**

MedDRA Term	Grading of adverse event				Total
	Grade 1	Grade 2	Grade 3	Grade 4	
Abdominal pain	-	-	1	-	1
Cerebrovascular accident	-	-	-	1	1
Chest pain	2	-	-	-	2
Clostridium difficile colitis	-	1	-	-	1
Convulsion	3	4	-	-	7
Depressed level of consciousness	-	-	-	1	1
Dyspnoea	1	-	-	-	1
Fall	3	-	-	-	3
Headache	1	1	-	-	2
Hypersensitivity	-	1	-	-	1
Hypotension	-	1	-	-	1
Pain	-	2	-	-	2
Pneumonia	-	1	-	-	1
Pruritus	-	1	-	-	1
Pseudoseizures	1	-	-	-	1
Respiratory depression	-	-	-	1	1
Tachycardia	1	-	-	-	1
Vomiting	1	-	-	-	1
Vomiting/Nausea	1	-	-	-	1
<b>Total</b>	<b>14</b>	<b>12</b>	<b>1</b>	<b>3</b>	<b>30</b>
<b>Percent</b>	<b>46%</b>	<b>40%</b>	<b>3.3%</b>	<b>10%</b>	<b>100%</b>

*Across RAMPART and ESETT, 30 adverse events were recorded in 23 pPNES patients (29%).*

*MedDRA=Medical Dictionary for Regulatory Activities (adverse event classification dictionary)*



## SUPPLEMENTARY MATERIAL

### **Misdiagnosis of prolonged psychogenic nonepileptic seizures as status epilepticus: incidence and associated risks**

#### Authors:

Johannes Jungilligens \*<sup>a</sup>

Rosa Michaelis<sup>a, b</sup>

Stoyan Popkirov<sup>a</sup>

#### Affiliations:

<sup>a</sup> Department of Neurology, University Hospital Knappschafts Krankenhaus Bochum, Ruhr University Bochum, Bochum, Germany

<sup>b</sup> Department of Neurology, Gemeinschafts Krankenhaus Herdecke, University of Witten/Herdecke, Herdecke, Germany


#### \* Corresponding author:

Johannes Jungilligens, Dr. rer. nat.

Postal address: Klinik für Neurologie, Universitätsklinikum Knappschafts Krankenhaus Bochum, In der Schornau 23-25, 44892 Bochum, Germany.

E-Mail: johannes.jungilligens@rub.de

Phone: +49-234-299-0

**Figure S1: Flow diagram of literature review**

*Supplementary figure 1: An electronic search was performed using the MEDLINE database. The search was restricted to articles published up to January 2021. There were no language restrictions. We searched for clinical studies and clinical trials by using the Medical Subject Heading (Mesh) "Status Epilepticus/therapy". Clinical trials that recruited prehospital patients with status epilepticus and reported rates of misdiagnosis were eligible. Abstracts of the citations identified by the search were reviewed to determine eligibility for inclusion. We obtained full-text copies of all publications that might conceivably contain relevant data. The reference lists of all relevant publications were also examined for additional relevant studies*

**Table S1: Grading and MedDRA categorisation of adverse events in pPNES patients across RAMPART and ESETT**

MedDRA Term	Grading of adverse event				Total
	Grade 1	Grade 2	Grade 3	Grade 4	
Abdominal pain	-	-	1	-	1
Cerebrovascular accident	-	-	-	1	1
Chest pain	2	-	-	-	2
Clostridium difficile colitis	-	1	-	-	1
Convulsion	3	4	-	-	7
Depressed level of consciousness	-	-	-	1	1
Dyspnoea	1	-	-	-	1
Fall	3	-	-	-	3
Headache	1	1	-	-	2
Hypersensitivity	-	1	-	-	1
Hypotension	-	1	-	-	1
Pain	-	2	-	-	2
Pneumonia	-	1	-	-	1
Pruritus	-	1	-	-	1
Pseudoseizures	1	-	-	-	1
Respiratory depression	-	-	-	1	1
Tachycardia	1	-	-	-	1
Vomiting	1	-	-	-	1
Vomiting/Nausea	1	-	-	-	1
<b>Total</b>	<b>14</b>	<b>12</b>	<b>1</b>	<b>3</b>	<b>30</b>
<b>Percent</b>	<b>46%</b>	<b>40%</b>	<b>3.3%</b>	<b>10%</b>	<b>100%</b>

*Across RAMPART and ESETT, 30 adverse events were recorded in 23 pPNES patients (29%).*

*MedDRA=Medical Dictionary for Regulatory Activities (adverse event classification dictionary)*